BACKGROUND: Most studies of vascular disease in transplanted organs have used combinations involving disparities determined by genes of the major histocompatibility complex (MHC). This report describes examples of coronary vascular disease occurring in transplanted mouse hearts involving isolated, non-H2-determined incompatibilities. METHODS: Mice, incompatible in respect of HY, H4, or H60, were selected. For H60, the incompatibility depended on breeding congenic pairs or the introduction of H60 by transgenic methods because the latter method results in more widespread expression. Transplant survival was determined, and the appearance and prevalence of coronary artery vasculopathy (CAV) was established by appropriate histologic methods. RESULTS: Advanced changes of CAV were found at 56 days in transplants involving incompatibilities confined to HY or H4. In both combinations, skin grafts were also rejected. H60 incompatibility does not result in skin graft rejection and only a minority of heart transplants shows evidence of CAV. If heart transplants are preceded by skin grafts bearing both H60 and HY incompatibilities to promote "help" in generating immunity, H60 incompatible hearts develop advanced CAV. Heart transplants in all non-MHC categories ostensibly survive in excellent condition throughout this period despite their CAV. CONCLUSIONS: CAV can develop as a consequence of non-MHC incompatibilities alone and even when antigens are sparsely expressed on cardiac tissue. Presensitization leads to much more severe vascular disease. Human leukocyte antigen compatible kidney transplants may also develop vascular disease and patients manifesting reactivity to MHC antigens should also be more prone to develop vascular disease because of undetectable non-MHC incompatibilities.
BACKGROUND: Most studies of vascular disease in transplanted organs have used combinations involving disparities determined by genes of the major histocompatibility complex (MHC). This report describes examples of coronary vascular disease occurring in transplanted mouse hearts involving isolated, non-H2-determined incompatibilities. METHODS:Mice, incompatible in respect of HY, H4, or H60, were selected. For H60, the incompatibility depended on breeding congenic pairs or the introduction of H60 by transgenic methods because the latter method results in more widespread expression. Transplant survival was determined, and the appearance and prevalence of coronary artery vasculopathy (CAV) was established by appropriate histologic methods. RESULTS: Advanced changes of CAV were found at 56 days in transplants involving incompatibilities confined to HY or H4. In both combinations, skin grafts were also rejected. H60 incompatibility does not result in skin graft rejection and only a minority of heart transplants shows evidence of CAV. If heart transplants are preceded by skin grafts bearing both H60 and HY incompatibilities to promote "help" in generating immunity, H60 incompatible hearts develop advanced CAV. Heart transplants in all non-MHC categories ostensibly survive in excellent condition throughout this period despite their CAV. CONCLUSIONS: CAV can develop as a consequence of non-MHC incompatibilities alone and even when antigens are sparsely expressed on cardiac tissue. Presensitization leads to much more severe vascular disease. Human leukocyte antigen compatible kidney transplants may also develop vascular disease and patients manifesting reactivity to MHC antigens should also be more prone to develop vascular disease because of undetectable non-MHC incompatibilities.
Authors: Andreas Diefenbach; Elena Tomasello; Mathias Lucas; Amanda M Jamieson; Jennifer K Hsia; Eric Vivier; David H Raulet Journal: Nat Immunol Date: 2002-11-11 Impact factor: 25.606
Authors: Su Jeong Ryu; Ji Yeong Jeon; Jun Chang; Thomas J Sproule; Derry C Roopenian; Eun Young Choi Journal: Mol Cells Date: 2012-03-21 Impact factor: 5.034
Authors: Andrew G Masoud; Jiaxin Lin; Abul K Azad; Maikel A Farhan; Conrad Fischer; Lin F Zhu; Hao Zhang; Banu Sis; Zamaneh Kassiri; Ronald B Moore; Daniel Kim; Colin C Anderson; John C Vederas; Benjamin A Adam; Gavin Y Oudit; Allan G Murray Journal: J Clin Invest Date: 2020-01-02 Impact factor: 14.808
Authors: László Fónyad; Kazunobu Shinoda; Evan A Farkash; Martin Groher; Divya P Sebastian; A Marcell Szász; Robert B Colvin; Yukako Yagi Journal: Diagn Pathol Date: 2015-03-28 Impact factor: 2.644
Authors: Celina Garcia; Luiz Gustavo Dubois; Anna Lenice Xavier; Luiz Henrique Geraldo; Anna Carolina Carvalho da Fonseca; Ana Helena Correia; Fernanda Meirelles; Grasiella Ventura; Luciana Romão; Nathalie Henriques Silva Canedo; Jorge Marcondes de Souza; João Ricardo Lacerda de Menezes; Vivaldo Moura-Neto; Fernanda Tovar-Moll; Flavia Regina Souza Lima Journal: BMC Cancer Date: 2014-12-08 Impact factor: 4.430